Rare Diseases Symptoms Automatic Extraction

Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema.

[coats disease]

Intravitreal application of triamcinolone and bevacizumab in Coats' disease with macular edema to improve visual outcome.Testing of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography, fluorescein angiography, 30° perimetry, and full-field electroretinography were performed at initial and follow-up visits. Medical treatment consisted of intravitreal injection of 1.25 mg bevazicumab and 1.25 mg triamcinolone, followed by intravitreal injections of 1.25 mg bevazicumab at weeks 4 and 10. Follow-up was 87 weeks.Perimetric results, including a temporal absolute scotoma and reduced electroretinographic amplitudes (photopic and scotopic conditions), did not significantly change during the follow-up, but foveal retinal thickness decreased from 505 μm to 212 μm, and BCVA increased from 0.3 at baseline to 1.25 and remained stable during subsequent follow-up.Combined intravitreal treatment with bevacizumab and triamcinolone resulted in significant decrease of central retinal thickness and improved visual acuity in this case report. Severe local or systemic side-effects were not observed.

Diseases presenting "severe local or systemic side-effects" symptom

  • coats disease

You can validate or delete this automatically detected symptom